Vildagliptin / Metformin hydrochloride Accord

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

metformin hydrochloride, vildagliptin

Available from:

Accord Healthcare S.L.U.

ATC code:

A10BD08

INN (International Name):

vildagliptin / metformin hydrochloride

Therapeutic group:

Narkotika anvendt i diabetes

Therapeutic area:

Diabetes Mellitus, Type 2

Therapeutic indications:

Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Product summary:

Revision: 2

Authorization status:

autoriseret

Authorization date:

2022-03-24

Patient Information leaflet

                                33
B. INDLÆGSSEDDEL
34
INDLÆGSSEDDEL: INFORMATION TIL BRUGEREN
VILDAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/850 MG
FILMOVERTRUKNE TABLETTER
VILDAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/1000 MG
FILMOVERTRUKNE TABLETTER
vildagliptin/metforminhydrochlorid
LÆS DENNE INDLÆGSSEDDEL GRUNDIGT, INDEN DU BEGYNDER AT TAGE DETTE
LÆGEMIDDEL, DA DEN
INDEHOLDER VIGTIGE OPLYSNINGER.
-
Gem indlægssedlen. Du kan få brug for at læse den igen.
-
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er
mere, du vil vide.
-
Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor
være med at give lægemidlet
til andre. Det kan være skadeligt for andre, selvom de har de samme
symptomer, som du har.
-
Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger,
herunder bivirkninger, som ikke
er nævnt i denne indlægsseddel. Se punkt 4.
Se den nyeste indlægsseddel på www.indlaegsseddel.dk
OVERSIGT OVER INDLÆGSSEDLEN
1.
Virkning og anvendelse
2.
Det skal du vide, før du begynder at tage Vildagliptin/Metformin
hydrochloride Accord
3.
Sådan skal du tage Vildagliptin/Metformin hydrochloride Accord
4.
Bivirkninger
5.
Opbevaring
6.
Pakningsstørrelser og yderligere oplysninger
1.
VIRKNING OG ANVENDELSE
De aktive stoffer i Vildagliptin/Metformin hydrochloride Accord,
vildagliptin og
metforminhydrochlorid, tilhører en gruppe lægemidler, der kaldes
”orale antidiabetika”.
Vildagliptin/Metformin hydrochloride Accord bruges til at behandle
voksne patienter med type 2-
diabetes (sukkersyge). Denne type diabetes kaldes også
ikke-insulinkrævende diabetes mellitus.
Vildagliptin/Metformin hydrochloride Accord bruges når diabetes ikke
er tilstrækkeligt kontrolleret
ved hjælp af kost og motion alene og/eller med andre lægemidler til
behandling af diabetes (insulin
eller sulfonylurinstoffer).
Du får type 2-diabetes, hvis kroppen ikke producerer insulin nok,
eller hvis det insulin kroppen
producerer, ikke fungerer så godt, som det skulle. Du kan også få
det, hvis kroppen producerer for
m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUMÉ
2
1.
LÆGEMIDLETS NAVN
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg
filmovertrukne tabletter
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg
filmovertrukne tabletter
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg
filmovertrukne tabletter
Hver filmovertrukket tablet indeholder 50 mg vildagliptin og 850 mg
metforminhydrochlorid
(svarende til 660 mg af metformin).
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg
filmovertrukne tabletter
Hver filmovertrukket tablet indeholder 50 mg vildagliptin og 1000 mg
metforminhydrochlorid
(svarende til 780 mg af metformin).
Alle hjælpestoffer er anført under pkt. 6.1.
3.
LÆGEMIDDELFORM
Filmovertrukket tablet (tablet).
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg
filmovertrukne tabletter.
Gul, oval, bikonveks, filmovertrukket tablet, præget med ”GG2”
på den ene side og glat på den anden
side. Tabletten måler ca. 20,15

8,00 mm.
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg
filmovertrukne tabletter
Mørkegul, oval, bikonveks, filmovertrukket tablet, præget med
”GG3” på den ene side og glat på den
anden side. Tabletten måler ca. 21,11

8,38 mm.
4.
KLINISKE OPLYSNINGER
4.1
TERAPEUTISKE INDIKATIONER
Vildagliptin/Metformin hydrochloride Accord er indiceret som
supplement til diæt og motion for at
forbedre glykæmisk kontrol hos voksne med type 2-diabetes mellitus:

hos patienter, der er utilstrækkeligt kontrolleret med metformin
hydrochlorid alene.

hos patienter som allerede behandles med kombinationen af vildagliptin
og metformin
hydrochlorid, i form af separate tabletter.

i kombination med andre lægemidler til behandling af diabetes,
herunder insulin, når disse ikke
giver tilstrækkelig glykæmisk kontrol (se også pkt. 4.4, 4.5 og 5.1
for tilgængelige oplysninger
om forskellige kombinationer).
4.2
DOSERING OG ADMINISTRATION
Dosering
_Voksne med normal nyrefunktion (GFR ≥ 90 ml/min) _
Doseringen af antihyperg
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-06-2023
Public Assessment Report Public Assessment Report Bulgarian 17-06-2022
Patient Information leaflet Patient Information leaflet Spanish 01-06-2023
Public Assessment Report Public Assessment Report Spanish 17-06-2022
Patient Information leaflet Patient Information leaflet Czech 01-06-2023
Public Assessment Report Public Assessment Report Czech 17-06-2022
Patient Information leaflet Patient Information leaflet German 01-06-2023
Public Assessment Report Public Assessment Report German 17-06-2022
Patient Information leaflet Patient Information leaflet Estonian 01-06-2023
Public Assessment Report Public Assessment Report Estonian 17-06-2022
Patient Information leaflet Patient Information leaflet Greek 01-06-2023
Public Assessment Report Public Assessment Report Greek 17-06-2022
Patient Information leaflet Patient Information leaflet English 01-06-2023
Public Assessment Report Public Assessment Report English 17-06-2022
Patient Information leaflet Patient Information leaflet French 01-06-2023
Public Assessment Report Public Assessment Report French 17-06-2022
Patient Information leaflet Patient Information leaflet Italian 01-06-2023
Public Assessment Report Public Assessment Report Italian 17-06-2022
Patient Information leaflet Patient Information leaflet Latvian 01-06-2023
Public Assessment Report Public Assessment Report Latvian 17-06-2022
Patient Information leaflet Patient Information leaflet Lithuanian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-06-2023
Public Assessment Report Public Assessment Report Lithuanian 17-06-2022
Patient Information leaflet Patient Information leaflet Hungarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 01-06-2023
Public Assessment Report Public Assessment Report Hungarian 17-06-2022
Patient Information leaflet Patient Information leaflet Maltese 01-06-2023
Public Assessment Report Public Assessment Report Maltese 17-06-2022
Patient Information leaflet Patient Information leaflet Dutch 01-06-2023
Public Assessment Report Public Assessment Report Dutch 17-06-2022
Patient Information leaflet Patient Information leaflet Polish 01-06-2023
Public Assessment Report Public Assessment Report Polish 17-06-2022
Patient Information leaflet Patient Information leaflet Portuguese 01-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 01-06-2023
Public Assessment Report Public Assessment Report Portuguese 17-06-2022
Patient Information leaflet Patient Information leaflet Romanian 01-06-2023
Public Assessment Report Public Assessment Report Romanian 17-06-2022
Patient Information leaflet Patient Information leaflet Slovak 01-06-2023
Public Assessment Report Public Assessment Report Slovak 17-06-2022
Patient Information leaflet Patient Information leaflet Slovenian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 01-06-2023
Public Assessment Report Public Assessment Report Slovenian 17-06-2022
Patient Information leaflet Patient Information leaflet Finnish 01-06-2023
Public Assessment Report Public Assessment Report Finnish 17-06-2022
Patient Information leaflet Patient Information leaflet Swedish 01-06-2023
Public Assessment Report Public Assessment Report Swedish 17-06-2022
Patient Information leaflet Patient Information leaflet Norwegian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 01-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 01-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 01-06-2023
Patient Information leaflet Patient Information leaflet Croatian 01-06-2023
Public Assessment Report Public Assessment Report Croatian 17-06-2022